Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep867 | Thyroid cancer | ECE2015

The two tyrosine kinase inhibitors, CLM29 and CLM3, have antineoplastic activity in primary cultures from anaplastic thyroid cancer obtained from fine needle aspiration

Ferrari Silvia Martina , Fallahi Poupak , Motta Concettina La , Materazzi Gabriele , Ragusa Francesca , Limongi Francesca , Ruffilli Ilaria , Settimo Federico Da , Miccoli Paolo , Antonelli Alessandro

Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine malignancy, with a mean survival of about 6 months. Until now, the most effective therapy for ATC comprises a multimodal treatment protocol, including surgery, chemotherapy (doxorubicin and cisplatin), and hyperfractionated accelerated external beam radiotherapy, with a median patient survival of 10 months. A possible increase in the effectiveness of the treatment could be achieved testing the sensitivity of &...

ea0032p1081 | Thyroid cancer | ECE2013

A novel multi-target pyrazolopyrimidine derivative with anti-neoplastic properties, CLM29, is active against medullary thyroid cancer in vitro and in vivo

Fallahi Poupak , Ferrari Silvia Martina , Bocci Guido , La Motta Concettina , Ruffilli Ilaria , Di Domenicantonio Andrea , Corrado Alda , Mancusi Caterina , Danesi Romano , Da Settimo Federico , Miccoli Paolo , Antonelli Alessandro

Introduction: CLM29, a pyrazolo[3,4-d]pyrimidine compound, inhibits several targets (including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor and has an anti-angiogenic effect). Recently it has been shown to inhibit proliferation and migration in primary papillary dedifferentiated thyroid cancer cells. The aim of this study is to evaluate the anti-tumor activity of CLM29 in medullary thyroid cancer (MTC).<p c...